Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) today announced a strategic in-licensing agreement with Chinas Hansoh Pharmaceuticals (03692: HK) for exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau for a dual GLP-1/GIP receptor agonist currently in Phase III testing
Further exploration through randomized controlled trials would be needed.
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
Replenza is also associated with supporting skin elasticity
Romigi A et al
However, side effects can occur, although they are rare
Hypertension 75(6):13341357
US$ 24.66
US$ 27.23
US$ 25.76
